Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS phase 3 trial of UGN-102 versus TURBT in low-grade intermediate-risk non-muscle-invasive bladder cancer
MOH_2021-05-23_009968Phase 3Not yet recruiting
- Sponsor
- UroGen Pharma
- Start
- May 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zusduri in bladder cancer and non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by UroGen Pharma. Primary endpoint: Disease-free survival. Planned start May 2021; status: not yet recruiting.
02
Drugs
zusduri
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on MOH_2021-05-23_009968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-05-23_009968.